Rituximab with peripheral blood stem cell transplantation in CD20 lymphoproliferative disorders

Haematologica. 2001 Oct;86(10):1104-5.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20*
  • Antineoplastic Agents / administration & dosage*
  • Female
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Leukapheresis / methods
  • Lymphoproliferative Disorders / drug therapy*
  • Lymphoproliferative Disorders / immunology*
  • Lymphoproliferative Disorders / therapy
  • Male
  • Middle Aged
  • Neoplasm, Residual / drug therapy
  • Remission Induction
  • Rituximab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • Rituximab